RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response.

ABSTRACT: Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test

SUBMITTER: Penn-Nicholson A 

PROVIDER: S-EPMC7248089 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature